<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82996">
  <stage>Registered</stage>
  <submitdate>20/07/2008</submitdate>
  <approvaldate>4/08/2008</approvaldate>
  <actrnumber>ACTRN12608000388314</actrnumber>
  <trial_identification>
    <studytitle>Safety and efficacy of Neurotec in reducing pain in patients with diabetic neuropathy - a single armed phase II trial</studytitle>
    <scientifictitle>Safety and efficacy of Neurotec in reducing pain in patients with diabetic neuropathy - a single armed phase II trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic Neuropathy</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral 120 mg capsules of Neurotec  twice a day for 12 weeks and once a day for another 4 weeks - a herbal exract</interventions>
    <comparator>There is no control group.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain measured by Visual Analogos Scale(VAS)</outcome>
      <timepoint>baseline, 2, 4, 8, 12, 16 and 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Michigan Diabetic Neuropathy score</outcome>
      <timepoint>baseline, 2, 4, 8, 12, 16 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>UK Diabetic Neuropathy score</outcome>
      <timepoint>baseline, 2, 4, 8, 12, 16 and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Semmes-Weinstein monofilament test for peripheral sensory neuropathy</outcome>
      <timepoint>baseline, 2, 4, 8, 12, 16 and 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>having diabetic I or II 
having pain and paresthesia interfering with every day activities
Diminished anckle reflex
Abnormal 128 Hz vibration test</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unwilling to sign a written consent
Non-diabetic neuropathy
Wound infection or infection in extremities
ischaemic heart disease
Heart failure
reeiving immunosuppresive drugs, corticosteroids, chemotherapy, radiotherapy
Alcohol and substance misuse
Electrolyte disturbances
History of known hypersensitivity to drugs
Haemodialysis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/08/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tehran University of Medical Sciences</primarysponsorname>
    <primarysponsoraddress>Ghods St.,
Keshavars beulevard,
Tehran, Iran</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>ParsRoos</fundingname>
      <fundingaddress>No 568, 13th Alley
Hormozan St.,
Shahrak-e-Gharb, 
Tehran, 14667-93143
Iran</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Shariati Hospital</sponsorname>
      <sponsoraddress>North Karegar street, 
Tehran, Iran</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase II, single armed, trial of Safety and Efficacy of Neurotec, a herbal extract. After signing a consent form 10 paients will be recruited into this trial during which they will recieve oral capsules of Neurotec twice a day for 12 weeks and once a day for another 4 weeks. Every 2 weeks a detailed clinical and laboratory examination will be carried out. this will continue up to 24 weeks. Primary outcome measure is pain which will be measured on 2 week intervals. Secondary outcome measures are michigan and UK diabetic neuropathy score.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Endocrine and Metablism research Centre Ethic committee</ethicname>
      <ethicaddress>5th Floor, Shariati Hospital, North Karegar street, Tehran, Iran</ethicaddress>
      <ethicapprovaldate>29/04/2008</ethicapprovaldate>
      <hrec>E-0005</hrec>
      <ethicsubmitdate>29/03/2008</ethicsubmitdate>
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>pezhman madani</name>
      <address>5th Floor, 
Shariati Hospital, 
North Karegar street, 
Tehran, Iran</address>
      <phone>0098-21-84902786</phone>
      <fax>0098-21-88029399</fax>
      <email>pezhman@iums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ramin Heshmat</name>
      <address>5th Floor, 
Shariati Hospital, 
North Karegar street, 
Tehran, Iran</address>
      <phone>0098-21-84902786</phone>
      <fax>0098-21-88029399</fax>
      <email>rheshmat@tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ramin Heshmat</name>
      <address>5th Floor, 
Shariati Hospital, 
North Karegar street, 
Tehran, Iran</address>
      <phone>0098-21-84902786</phone>
      <fax>0098-21-88029399</fax>
      <email>rheshmat@tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>